Pulmonx (LUNG) Announces Third Quarter 2025 Financial Earnings Results

Pulmonx Corporation (LUNG) today announced its financial results for the most recent quarter, showcasing a strong performance that exceeded expectations. The company reported earnings per share of -$0.34, beating the consensus estimate of -$0.41 by $0.07. Additionally, Pulmonx achieved quarterly revenue of $21.5 million, surpassing the revenue estimate of $20.98 million by $522,000.

Key Highlights:

• Pulmonx reported third quarter 2025 revenue of $21.5 million, a 5% increase year-over-year.
• International revenue reached $7.5 million, marking a 15% year-over-year growth.
• U.S. revenue was $14.0 million, reflecting a 1% increase from the previous year.
• Gross margin for the quarter was 75%, up from 74% in the same period last year.
• The company updated its full-year 2025 revenue outlook to between $89 million and $90 million.
• Glen French was reappointed as President and CEO, with Derrick Sung appointed as COO and CFO.

In the third quarter of 2025, Pulmonx Corporation demonstrated solid financial performance, achieving a total revenue of $21.5 million, which represents a 5% increase compared to the same quarter in 2024. The growth was driven by a notable 15% increase in international revenue, while U.S. revenue saw a modest 1% rise. The company reported a gross margin of 75%, indicating effective cost management and operational efficiency. Glen French, the President and CEO, emphasized the potential for further growth, stating, “While our third quarter performance broadly met expectations, we feel there is a meaningful opportunity to leverage our operational foundation and refine execution to expand Zephyr Valve treatment volumes.”

Looking ahead, Pulmonx has revised its financial outlook for the full year 2025, projecting total revenue to fall between $89 million and $90 million. The company anticipates a gross margin of approximately 73% and total operating expenses in the range of $125 million to $126 million. This guidance reflects the company’s commitment to sustainable growth while navigating potential external challenges, including tariffs and macroeconomic factors. The management remains focused on enhancing the quality of life for patients with severe emphysema through its innovative treatment solutions.

Pulmonx Corporation (LUNG) has experienced a rollercoaster ride in its stock price, with a remarkable 21.51% increase over the past week, signaling a potential rebound after a challenging year. However, the one-year performance paints a stark picture, with a staggering decline of 72.32%, reflecting significant investor concerns. The company’s fundamentals reveal a troubling landscape, highlighted by a negative price-to-earnings ratio of -1.38 and a return on invested capital that is also in the red at -1.03. Despite a commendable revenue growth rate of 22.18% over the past two years, the net profit margin remains negative at -0.63%, indicating ongoing profitability challenges. This juxtaposition of short-term price recovery against a backdrop of fundamental weaknesses suggests that while traders may be optimistic, long-term investors should tread carefully. The volatility in LUNG’s stock could be indicative of speculative trading rather than a solid turnaround in its financial health. As the company navigates these turbulent waters, stakeholders will be keenly watching for any signs of sustainable improvement in its financial metrics.

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.